NeoGenomics launches an FDA-approved PTEN IHC companion diagnostic to identify prostate cancer patients eligible for AstraZeneca’s Truqap.
Find out how AstraZeneca’s Truqap approval could reshape PTEN-deficient prostate cancer treatment and biomarker testing.